The DOI matches its Crossref record.
Overexpression of Orphan G–Protein-Coupled Receptor, Gpr49 , in Human Hepatocellular Carcinomas With β–Catenin Mutations
Open accessAbstract
To identify the genes responsible for carcinogenesis and progression of hepatocellular carcinoma (HCC), we screened differentially expressed genes in several human HCC cell lines. Among these genes, Gpr49 was up–regulated in PLC/PRF/5 and HepG2. Gpr49 is a member of the glycoprotein hormone receptor subfamily, which includes the thyroid–stimulating hormone receptor (TSHR). However, Gpr49 remains to be an orphan G–protein–coupled receptor. By real–time quantitative reverse transcriptase polymerase chain reaction (RT–PCR) analysis, overexpression (>3–fold increase compared with the corresponding noncancerous liver tissue) of Gpr49 mRNA was observed in 18 of 38 (47%) HCCs compared with corresponding noncancerous livers. Clinicopathologically, overexpression of Gpr49 was frequently observed in HCC with mutation in β–catenin exon 3 (14 of 16 cases, 87.5%). Moreover, introduction of mutant β–catenin into mouse hepatocytes in culture caused up–regulation of the Gpr49 mouse homologue. Therefore, Gpr49 is likely to be a target gene activated by Wnt–signaling in HCC. In conclusion, although much is still unknown, Gpr49 may be critically involved in the development of HCCs with β–catenin mutations and has the potential to be a new therapeutic target in the treatment of HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Identification of stem cells in small intestine and colon by marker gene Lgr5
Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P. J., et al. (2007) · Nature · doi:10.1038/nature06196 · Cited by 5,687
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Zucman-Rossi, J., Jeannot, E., Van Nhieu, J. T., Scoazec, J.-Y., Guettier, C., Rebouissou, S., Bacq, Y., Leteurtre, E., Paradis, V., Michalak, S., et al. (2006) · Hepatology · doi:10.1002/hep.21068 · Cited by 760
The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength
de Lau, W., Peng, W. C., Gros, P., & Clevers, H. (2014) · Genes & Development · doi:10.1101/gad.235473.113 · Cited by 656
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry
Bioulac-Sage, P., Rebouissou, S., Thomas, C., Blanc, J.-F., Saric, J., Sa Cunha, A., Rullier, A., Cubel, G., Couchy, G., Imbeaud, S., et al. (2007) · Hepatology · doi:10.1002/hep.21743 · Cited by 590
The Intestinal Wnt/TCF Signature
Van der Flier, L. G., Sabates–Bellver, J., Oving, I., Haegebarth, A., De Palo, M., Anti, M., Van Gijn, M. E., Suijkerbuijk, S., Van de Wetering, M., Marra, G., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.08.039 · Cited by 513
β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis
Monga, S. P. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.056 · Cited by 487
Dysregulation of Wnt/β-Catenin Signaling in Gastrointestinal Cancers
White, B. D., Chien, A. J., & Dawson, D. W. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.001 · Cited by 469
Wnt Signaling, Lgr5, and Stem Cells in the Intestine and Skin
Haegebarth, A., & Clevers, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080758 · Cited by 353
Leucine-Rich Repeat-Containing G-Protein-Coupled Receptors as Markers of Adult Stem Cells
Barker, N., & Clevers, H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.002 · Cited by 341
Zucman-Rossi, J., Benhamouche, S., Godard, C., Boyault, S., Grimber, G., Balabaud, C., Cunha, A. S., Bioulac-Sage, P., & Perret, C. (2007) · Oncogene · doi:10.1038/sj.onc.1209824 · Cited by 256
TNIK inhibition abrogates colorectal cancer stemness
Masuda, M., Uno, Y., Ohbayashi, N., Ohata, H., Mimata, A., Kukimoto-Niino, M., Moriyama, H., Kashimoto, S., Inoue, T., Goto, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms12586 · Cited by 168
Cholestasis is a marker for hepatocellular carcinomas displaying β‐catenin mutations
Audard, V, Grimber, G., Elie, C., Radenen, B., Audebourg, A., Letourneur, F., Soubrane, O., Vacher‐Lavenu, M., Perret, C., Cavard, C., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2169 · Cited by 162
LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Gong, X., Azhdarinia, A., Ghosh, S. C., Xiong, W., An, Z., Liu, Q., & Carmon, K. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0114 · Cited by 130
Hale, G., Liu, X., Hu, J., Xu, Z., Che, L., Solomon, D., Tsokos, C., Shafizadeh, N., Chen, X., Gill, R., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.122 · Cited by 73
LGR5 is associated with tumor aggressiveness in papillary thyroid cancer
Michelotti, G., Jiang, X., Sosa, J. A., Diehl, A. M., & Henderson, B. B. (2015) · Oncotarget · doi:10.18632/oncotarget.5330 · Cited by 31
“In recent years, multiple studies have demonstrated that LGR5 is overexpressed in various types of tumors, including colorectal [21], ovarian [22], hepatocellular [23], basal cell [24], and esophageal cancers [25].”
BackgroundTargeted Cancer Stem Cell Therapeutics: An Update
Fatima, N., Umar, M., Ambreen, S., Shaququzzaman, M., Alam, M. M., & Ali, R. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266275014240110071351 · Cited by 6
Metadata
- Authors
- Yamamoto, Y., Sakamoto, M., Fujii, G., Tsuiji, H., Kenetaka, K., Asaka, M., & Hirohashi, S.
- Venue
- Hepatology
- Published
- 2003-03
- Volume
- 37
- Issue
- 3
- Pages
- 528-533
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2132705689
- Cited by
- 200
- References
- 0
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.